Wall Street analyst estimates for NewAmsterdam Pharma Company N.V. (NAMS): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $30.3M | $6.0M – $41.8M | -$1.89 | 10 |
| 2027E | $153M | $17.5M – $437M | -$1.56 | 10 |
| 2028E | $402M | $147M – $1.2B | -$0.46 | 10 |
Figures in USD · consensus as of November 5, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (−2 sell to +2 buy) | 0.90 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-17 | $-0.38 | ||
| 2026-11-04 | $-0.14 | $-0.47 | +70.1% |
| 2026-08-05 | $-0.52 | $-0.48 | -7.9% |
| 2026-05-07 | $-0.40 | $-0.46 | +13.0% |
| 2026-02-18 | $-0.63 | $-0.43 | -45.1% |
| 2025-11-05 | $-0.61 | $-0.38 | -60.5% |
| 2025-08-06 | $-0.15 | $-0.52 | +71.2% |
| 2025-05-08 | $-0.49 | $-0.45 | -8.9% |
Valuation Ratios
| Price / Book | 4.12 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $102.7M | $14.1M | $45.6M | $22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | $59,000 |
| Gross Profit | 0 | 0 | $102.7M | $14.1M | $45.6M | $22.4M |
| Research & Development | $4.9M | $29.0M | $86.7M | $159.4M | $151.4M | $141.8M |
| Selling, General & Admin | $1.7M | $5.7M | $19.5M | $37.6M | $70.4M | $106.3M |
| Operating Expenses | $6.6M | $35.0M | $106.3M | $197.1M | $221.9M | $248.1M |
| Operating Income | -$6.6M | -$35.0M | -$3.6M | -$183.0M | -$176.3M | -$225.7M |
| EBITDA | -$6.6M | -$41.4M | -$22.3M | -$176.9M | -$241.5M | -$242.3M |
| Interest Expense | 0 | $411,000 | $287,000 | $6.8M | 0 | 0 |
| Pre-tax Income | -$7.0M | -$41.8M | -$22.6M | -$176.9M | -$241.6M | -$203.8M |
| Income Tax | 0 | 0 | 0 | $27,000 | -$1,000 | 0 |
| Net Income | -$7.0M | -$41.8M | -$22.6M | -$176.9M | -$241.6M | -$203.8M |
| EPS | $0.00 | -$3.34 | -$1.19 | -$2.15 | -$2.56 | -$1.75 |
| EPS (Diluted) | $0.00 | -$3.34 | -$1.19 | -$2.15 | -$2.56 | -$1.75 |
| Shares Outstanding (Diluted) | 17.8 M | 17.8 M | 19.0 M | 82.2 M | 94.4 M | 114.4 M |
Price
| Price | $20.93 (closing price, November 4, 2026) |
| Market Cap | $2.4B |
| Exchange | NASDAQ |
| Country | NL |
Related companies: MDGL · VKTX · DNLI · AMLX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks